TITLE

FDA Warnings Dominate Pharmaceutical News

AUTHOR(S)
Elliott, William T.
PUB. DATE
January 2008
SOURCE
Neurology Alert;Jan2008, Vol. 26 Issue 5, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Thee article offers updates on the U.S. Food and Drug Administration (FDA). The agency and its advisory committee have issued warnings on several drugs including erythropoiesis-stimulating agents, oseltamivir and zanamivir for the treatment of influenza and rosiglitazone for the treatment of type 2 diabetes. Meanwhile, it has approved the over-the-counter sales of cetirizine 5 mg plus pseudoephedrine HCL 120 mg.
ACCESSION #
28523297

 

Related Articles

  • NEWSLINE: New Humalog KwikPen Strength Approved.  // Monthly Prescribing Reference;Jul2015, Vol. 31 Issue 7, pA8 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to the Humalog KwikPen insulin lispro from American pharmaceutical company Eli Lilly & Co. designed to improve glycemic control in patients with type 1 and type 2 diabetes.

  • FDA Clears Trio of Type 2 Diabetes Medications.  // Chain Drug Review;3/18/2013, Vol. 35 Issue 5, p86 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of drug treatments for type 2 diabetes, including Nesina or alogliptin tablets, Kazano or alogliptin and metformin hydrochloride tablets, and Oseni or alogliptin and pioglitazone tablets.

  • FDA Actions.  // Critical Care Alert;Dec2009 Pharmacology Watch, p2 

    The article reports on the approval of the Food and Drug Administration (FDA) on the use of IV antiviral peramivir for treatment of inpatients with 2009 H1N1 influenza in the U.S.

  • New molecular entities/new biologics.  // Formulary;Apr2003, Vol. 38 Issue 4, p182 

    Reports on the U.S. Food and Drug Administration's approval of enfuvirtide, an anti-HIV drug. Efficacy; Safety; Dosing; Availability; Cost.

  • FDA Warnings Dominate Pharmaceutical News. Elliott, William T. // Clinical Cardiology Alert;Jan2008, Vol. 27 Issue 1, Special section p1 

    FDA warnings for existing drugs dominate pharmaceutical news this month. The FDA and its advisory committees have issued warnings on erythropoiesis-stimulating agents, oseltamivir (Tamiflu) and zanamivir (Relenza) for the treatment of influenza, rosiglitazone (Avandia) for the treatment of type...

  • FDA Actions.  // Clinical Cardiology Alert;Sep2007, Vol. 26 Issue 9, p2 

    This section offers news briefs on drug approvals of the U.S. Food and Drug Administration (FDA). It says that the approval of raloxifene has been recommended by the Oncologic Drugs Advisory Committee for the indication of breast cancer prevention in high risk women. The restricted use of...

  • NEW INDICATIONS.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p78 

    Reports on the U.S. Food and Drug Administration's approval of Paxil CR's controlled-release selective serotonin reuptake inhibitor and Novartis Pharmaceuticals' oral antidiabetes agent Starlix for drug indications.

  • Drug Gets OK. Webb, Marion // San Diego Business Journal;3/21/2005, Vol. 26 Issue 12, p27 

    The article reports that Amylin Pharmaceuticals Inc. announced March 16, 2005 that the U.S. Food and Drug Administration approved its diabetes drug Symlin. The San Diego, California-based company said that Symlin, or pramlintide acetate, will be made available in 90 days for patients with type-1...

  • Linagliptin approved for type 2 diabetes. Traynor, Kate // American Journal of Health-System Pharmacy;6/15/2011, Vol. 68 Issue 12, p1059 

    The article reports that the Food and Drug Administration (FDA) approved linagliptin, marketed as Tradjenta by Boehringer Ingelheim and Eli Lilly and Company, for use in glycemic control in type 2 diabetes mellitus (DM2) patients. It mentions that the drug is a dipeptidyl peptidase-4 inhibitor,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics